Information Provided By: 
Fly News Breaks for January 7, 2016
DVAX
Jan 7, 2016 | 11:42 EDT
Cowen analyst Phil Nadeau said Dynavax reported strongly positive data from the Phase III HBV-23 trial of Heplisav-B, and likely supports approval during the second half of 2016. Nadeau expects Heplisav to eventually become the market leading HBV vaccine and said the company is now a likely takeout candidate. The analyst views shares as significantly undervalued following today's derisking event and reiterates his Outperform rating and $60 price target on shares.
News For DVAX From the Last 2 Days
There are no results for your query DVAX
